Agaplesion Evangelisches Krankenhaus Mittelhessen gGmbH
- Address
- lock Available on a paid plan
Agaplesion Evangelisches Krankenhaus Mittelhessen - Pulmonary Research Center
Agaplesion Evangelisches Krankenhaus Mittelhessen gGmbH is a distinguished medical institution actively engaged in advanced clinical research for respiratory diseases. The center demonstrates specialized expertise in investigating novel therapeutic approaches for serious pulmonary conditions, with a particular focus on progressive fibrotic lung diseases.
- Idiopathic pulmonary fibrosis (IPF) treatment development
- Evaluation of innovative antifibrotic therapies
- Long-term efficacy and safety assessment in lung fibrosis patients
The research team participates in multi-center, randomized controlled trials aimed at characterizing the efficacy of emerging treatments for idiopathic pulmonary fibrosis. Their involvement in phase 2 studies demonstrates commitment to translating scientific advances into clinical practice, working to identify optimal dosing strategies and evaluate safety profiles of novel interventions for patients with this challenging progressive lung disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Rein Therapeutics Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Agaplesion Evangelisches Krankenhaus Mittelhessen gGmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW) | Rein Therapeutics Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| LTI-03 | 1 | Unknown | 2026-04-22 | 2026-04-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.